Fresenius SE & Co. (OTCMKTS:FSNUY) & The Pennant Group (NASDAQ:PNTG) Head-To-Head Review

The Pennant Group (NASDAQ:PNTG) and Fresenius SE & Co. (OTCMKTS:FSNUY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Volatility & Risk

The Pennant Group has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Fresenius SE & Co. has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for The Pennant Group and Fresenius SE & Co., as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
The Pennant Group	0	2	3	0	2.60
Fresenius SE & Co.	0	0	2	1	3.33

The Pennant Group presently has a consensus price target of $33.80, indicating a potential upside of 50.49%. Given The Pennant Group’s higher probable upside, equities analysts plainly believe The Pennant Group is more favorable than Fresenius SE & Co..

Profitability

This table compares The Pennant Group and Fresenius SE & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
The Pennant Group	3.40%	10.73%	4.00%
Fresenius SE & Co.	1.92%	9.06%	4.17%

Institutional & Insider Ownership

85.9% of The Pennant Group shares are owned by institutional investors. 5.4% of The Pennant Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares The Pennant Group and Fresenius SE & Co.”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Pennant Group	$695.24 million	1.11	$22.56 million	$0.76	29.55
Fresenius SE & Co.	$23.63 billion	N/A	$509.67 million	$0.19	64.79

Fresenius SE & Co. has higher revenue and earnings than The Pennant Group. The Pennant Group is trading at a lower price-to-earnings ratio than Fresenius SE & Co., indicating that it is currently the more affordable of the two stocks.

Summary

The Pennant Group beats Fresenius SE & Co. on 8 of the 14 factors compared between the two stocks.

About The Pennant Group

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

About Fresenius SE & Co.

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.